Oxidative stress induced by 6-OHDA stimulates autophagy flux, which enhances STX17-mediated autolysosome formation, leading to the degradation of autophagosomal contents. However, in response to ...

When targeting problem proteins involved in causing or spreading disease, a drug will often clog up a protein's active site so it can't function and wreak havoc. New strategies for dealing with these ...

ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease –– ARV-102 demonstrated ...

Researchers have identified the drivers of an extracellular protein degradation pathway, which could be the key to a new generation of therapeutics. In a recent study, chemists at Stanford University ...

Lycia Therapeutics Inc. has reported progress in its immunology pipeline that comprises lysosomal targeting chimera (LYTAC)-based protein degradation therapies. The company is advancing its two lead ...

The retromer complex controls protein sorting, transport, and disposal via the endolysosome system. It goes awry in neurodegenerative diseases, but how so remains unclear. Metabolism breaks down in ...

Therapeutics that leverage protein degradation as their primary mechanism of action appear to be a validated new therapeutic modality. The current clinical molecules are focused on degrading ...

Mitochondria generate most of the cell’s energy. However, when they become dysfunctional, damaged, or old, mitochondria can turn into pro-death organelles, which produce reactive oxygen species that ...

In a rare disease called mucolipidosis type II, people's hearts and abdomens swell, and their bones grow malformed. A lysosomal storage disorder, mucolipidosis type II causes edema of the internal ...

Before a chain of amino acids can become an active and useful protein, it must be processed and folded into the appropriate ...